Development of central nervous system (CNS) metastases in breast cancer (BC) is associated with poor prognosis. The incidence of CNS metastases in metastatic BC is reported to be about 10-16 %, but different subtypes of BC are associated with different risk of developing CNS metastases. We retrospectively analysed the risk of CNS metastases and the outcome in a cohort of 473 patients with metastatic BC. CNS metastases were diagnosed in 15.6 % of patients and median survival from diagnosis of CNS metastases was 7.53 (25th-75th 2.8-18.9) months. The risk of developing CNS metastases was higher in patients with grade 3, hormone receptor negative, HER2-positive, high Ki-67 BC. When compared to luminal A subtype, only HER2-positive BC was associated with increased risk of CNS metastases. Survival from diagnosis of CNS metastases was longer in patients with HER2-positive BC, while it was shorter in patients that did not receive any locoregional treatment, or with extra-CNS disease, or with more than 3 CNS lesions.
|Titolo:||Risk factors and survival outcomes in patients with brain metastases from breast cancer|
|Parole Chiave:||Brain metastases; Breast cancer; Immunophenotype; Prognostic factors; Risk factors; Adult; Aged; Aged, 80 and over; Brain Neoplasms; Breast Neoplasms; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Risk Factors; Survival Rate; Cancer Research; Oncology|
|Settore Scientifico Disciplinare:||Settore MED/01 - Statistica Medica|
Settore MED/06 - Oncologia Medica
|Data di pubblicazione:||2013|
|Digital Object Identifier (DOI):||10.1007/s10585-013-9594-5|
|Appare nelle tipologie:||01 - Articolo su periodico|